A Phase 2, Placebo-controlled, Randomised, Observer-blinded Trial To Evaluate The Safety, Tolerability And Immunogenicity Of A Clostridium Difficile Vaccine Administered As A 3-dose Regimen In Healthy Adults Aged 50 To 85 Years

Trial Profile

A Phase 2, Placebo-controlled, Randomised, Observer-blinded Trial To Evaluate The Safety, Tolerability And Immunogenicity Of A Clostridium Difficile Vaccine Administered As A 3-dose Regimen In Healthy Adults Aged 50 To 85 Years

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2017

At a glance

  • Drugs PF 6425090 (Primary)
  • Indications Clostridium infections
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 05 Dec 2017 Status changed from active, no longer recruiting to completed.
    • 14 Dec 2015 Planned number of patients changed from 185 to 749 as reported by ClinicalTrials.gov.
    • 19 May 2015 Planned number of patients changed from 276 to 185, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top